Drug Type Bispecific antibody |
Synonyms PM 1022, PM-1022 |
Target |
Mechanism PDL1 inhibitors(Programmed death-ligand 1 inhibitors), TIGIT inhibitors(T cell immunoglobulin and ITIM domains inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Phase 2 | CN | 11 Apr 2022 | |
Advanced cancer | Phase 1 | CN | 21 Jun 2022 |
Phase 1/2 | 15 | xluehesndr(ljygkmoksn) = 20% jewhfgfsrd (pcujzqrdbq ) View more | Positive | 24 May 2024 | |||